Iyo FoundationOne CDx (F1CDx) nzira yekuongorora cancer biomarker yakatenderwa neFDA muna Mbudzi 2017 kuti ione mazana matatu nemakumi maviri nemana emajini akasiyana anogona kuona shanduko dzinogoneka mumhando shanu dzebundu kusanganisira microsatellite instability (MSI) Tumor mutation load. Pamusoro pezvo, Keruis molecular mepu yekuongorora haingoite genetic test (nhamba yemajini akaonekwa ndeye 324), asi zvakare kuita protein yekuongorora (CISH, pyrosequencing), MSI kuyedza, nezvimwewo, zvinhu zvekuyedza zvakazara, uye mushonga. kusarudzwa kwakanyatsojeka.
Iyi bvunzo inobatsira kune varwere vane yakakwira MSI (MSI-H) kana kukanganisa kugadzirisa kukanganisa (dMMR) isingagadzirike kana metastatic gastrointestinal tumors, inogona kugamuchira pembrolizumab (Keytruda) uye inogona kubatsira. Kuonekwa kunogona zvakare kuona mamwe mamorekuru mamaki uye zvinangwa zvekutungamira kurapwa. Immune checkpoint inhibitors yakaratidza zvimwe zvinokatyamadza mhedzisiro muvarwere vane gomarara remudumbu, kunyanya mudumbu MSI-H tumors. Nhamburiko dziri kuitwa kuwedzera mwero wekupindura wecheki inhibitors mucolon uye pancreatic cancer kuburikidza nemusanganiswa kurapa. Vatsvagiri vari kuita tsvakiridzo pamubatanidzwa wemishonga yakawanda yekudzivirira zvirwere kuti vanzwisise kana vachigona kukonzeresa mhinduro mumamota asingashande pakurapa-mumiririri mumwe chete. Miedzo yemakiriniki yakagadzirwa, uye immunotherapy parizvino iri kusanganiswa nechemotherapy uye neradiation therapy mukuyedza kuvandudza mwero wekupindura kwezvirwere izvi.
Precision mishonga ichawedzera kukura mumakore mashoma anotevera, ichibvumira varapi kuti vaone biomarkers uye zvinangwa zvinobudirira kupfuura zvazvino matekinoroji. Kuburikidza nemushonga wakaringana wemushonga-genetiki, vazhinji varwere vegomarara vanozove nemukana wekusarudza yakanakisa inorwisa kenza mishonga yekuvandudza kurapwa, kuwedzera hupenyu nekuvandudza hupenyu.
http://www.onclive.com/web-exclusives/gastrointestinal-cancers-entering-age-of-precision-medicine?p=2
